QLife (QLIFE) Q1 2026 earnings summary

Executive summary

• Q1 2026 marked a strategic phase focused on partnership-driven growth and platform development, with limited revenues reflecting a phased commercialization approach.

• Advanced partnership discussions are ongoing in pharmacy distribution, IVD, and pharma segments, with expectations for agreements in 2026.

• The Egoo Health platform is positioned as a scalable, modular solution for decentralized blood testing, targeting chronic, rare, and critical diseases.

Financial highlights

• Revenue for Q1 2026 was KSEK 21, down from KSEK 110 in Q1 2025.

• EBITDA was KSEK -5,502 (Q1 2025: -5,269); net loss was KSEK -6,225 (Q1 2025: -6,120).

• Cash flow for the quarter was KSEK 5,387 (Q1 2025: -8); cash reserves at period end were KSEK 6,633 (Q1 2025: 2,707).

• Earnings per share before/after dilution were SEK -0.73 (Q1 2025: -0.73).

• Equity at period end was KSEK 1,905 (Q1 2025: -367).

Outlook and guidance

• Continued focus on developing the Egoo Health platform and pursuing commercial opportunities with partners in pharma, IVD, pharmacy, and consumer health.

• Timing of partnership agreements remains uncertain, but current engagement levels are seen as positive.